If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
577.50    5.50 (0.96%)
Bid:
577.00
Ask:
577.50
Spread: 0.50 (0.087%)
Market Cap: £1.56b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Directorate Change

24 Jun 2014 07:00

RNS Number : 3280K
Chemring Group PLC
24 June 2014
 



 FOR IMMEDIATE RELEASE 24 JUNE 2014

 

CHEMRING GROUP PLC

 

Directorate change

 

Michael Flowers appointed Group Chief Executive

 

Chemring Group PLC ("Chemring" or "the Group") announces that Michael Flowers has been appointed Group Chief Executive with immediate effect. Michael joined Chemring in 2006 and prior to today's appointment was Group Director, Countermeasures and a member of Chemring's Executive Committee.

 

Michael Flowers has spent 13 years in senior management positions within the defence industry. He previously served as an officer in the Australian Army for 22 years and was a graduate of the Australian Command and Staff College and the British Royal Military College of Science. After leaving the army, he was a senior manager at BAE Systems from 2001 to 2006, in programme and project management roles.

 

From 2006, he was Managing Director, Chemring Australia, where he established a state of the art countermeasures manufacturing facility and delivered substantial growth in the defence portfolio. In 2013, he was appointed Group Director, Munitions, with responsibility for Chemring's European munitions business. Michael led the successful sale of the European munitions business following the 2013 strategic review, working closely with Chemring's Board and advisers to negotiate and complete the disposal in May 2014.

 

Mark Papworth has stepped down from the Board of Chemring with immediate effect. 

 

Peter Hickson, Chairman of Chemring, said:

 

"Michael Flowers has a proven track record, both within the international defence industry and within Chemring, where he led our Australian business through a successful period of growth and, more recently, managed the complex disposal process of the European munitions business. Michael is extremely knowledgeable about our markets and is well qualified to lead Chemring as we capitalise on our world leading technologies in Countermeasures, Sensors & Electronics and Energetic Systems.

 

Much has been achieved during Mark Papworth's tenure, including a significant reorganisation and refocusing of the Group and a substantial reduction in the cost base and we are grateful for his leadership during this period.

 

We are now moving from a period of critical and significant change to one where we must take maximum advantage of the stronger platform that has been created. To achieve this, a different set of skills is required in the role of Chief Executive, in particular extensive knowledge and understanding of the defence markets in which we operate."

 

Michael Flowers has a beneficial shareholding of 80,680 Chemring shares.

 

There is no further information to be disclosed pursuant to paragraph 9.6.13R of the UK Listing Rules in relation to Michael Flowers' appointment as a director of Chemring.

 

Ends

 

 

 

 

For further information, contact:

 

Chemring Group PLC 01489 881 880

Peter Hickson, Chairman

Steve Bowers, Finance Director

Rupert Pittman, Group Director of Communications and Investor Relations

 

MHP Communications 020 3128 8100

Andrew Jaques

John Olsen

James White

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADDGDLSBDBGSX
Date   Source Headline
15th Aug 201812:20 pmRNSHolding(s) in Company
13th Aug 20187:00 amRNSINCIDENT AT CHEMRING COUNTERMEASURES
8th Aug 20187:12 amRNSDirectorate Change
6th Aug 20182:16 pmRNSHolding(s) in Company
1st Aug 20189:32 amRNSTotal Voting Rights
30th Jul 20181:24 pmRNSDirector/PDMR Shareholding
2nd Jul 201810:44 amRNSTotal Voting Rights
2nd Jul 20187:00 amRNSCONTRACT AWARDS
26th Jun 20183:54 pmRNSDirector/PDMR Shareholding
22nd Jun 20182:40 pmRNSBlock listing Interim Review
22nd Jun 20182:39 pmRNSBlock listing Interim Review
21st Jun 20187:00 amRNSINTERIM RESULTS
8th Jun 20181:37 pmRNSAdditional Listing
4th Jun 20187:00 amRNSTotal Voting Rights
24th May 20187:00 amRNSCONTRACT AWARDS
1st May 201810:26 amRNSTotal Voting Rights
1st May 20187:00 amRNSDirectorate Change
27th Apr 20183:41 pmRNSHolding(s) in Company
23rd Apr 201811:55 amRNSHolding(s) in Company
19th Apr 20187:00 amRNSContract Award
3rd Apr 20181:03 pmRNSTotal Voting Rights
23rd Mar 20187:00 amRNSChange of auditor
20th Mar 20182:17 pmRNSResult of AGM
20th Mar 20187:00 amRNSAGM Statement
1st Mar 201811:02 amRNSTotal Voting Rights
23rd Feb 201810:35 amRNSHolding(s) in Company
15th Feb 201810:23 amRNSNotice of AGM
8th Feb 20184:27 pmRNSHolding(s) in Company
5th Feb 201812:10 pmRNSHolding(s) in Company
1st Feb 201810:51 amRNSTotal Voting Rights
1st Feb 20187:00 amRNSContract Award
29th Jan 20185:38 pmRNSHolding(s) in Company
29th Jan 20182:30 pmRNSDirector/PDMR Shareholding
29th Jan 20182:28 pmRNSDirector/PDMR Shareholding
29th Jan 20182:25 pmRNSDirector/PDMR Shareholding
29th Jan 20182:25 pmRNSDirector/PDMR Shareholding
29th Jan 20181:47 pmRNSDirector/PDMR Shareholding
29th Jan 20181:43 pmRNSDirector/PDMR Shareholding
29th Jan 20181:38 pmRNSDirector/PDMR Shareholding
29th Jan 20181:38 pmRNSDirector/PDMR Shareholding
29th Jan 201810:46 amRNSTransaction in Own Shares
29th Jan 201810:23 amRNSTransaction in Own Shares
26th Jan 201812:32 pmRNSHolding(s) in Company
26th Jan 201812:26 pmRNSHolding(s) in Company
23rd Jan 201810:41 amRNSHolding(s) in Company
22nd Jan 201810:11 amRNSDirector/PDMR Shareholding
22nd Jan 201810:08 amRNSDirector/PDMR Shareholding
22nd Jan 201810:03 amRNSDirector/PDMR Shareholding
22nd Jan 201810:02 amRNSDirector/PDMR Shareholding
22nd Jan 201810:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.